about
Functional MRI for the prediction of treatment response in head and neck squamous cell carcinoma: potential and limitationsFunctional magnetic resonance imaging techniques and their development for radiation therapy planning and monitoring in the head and neck cancersHuman cervical lymphadenopathy: evaluation with in vivo 1H-MRS at 1.5 T.Salivary gland tumors at in vivo proton MR spectroscopy.Delayed complications of radiotherapy treatment for nasopharyngeal carcinoma: imaging findings.Monitoring of treatment response after chemoradiotherapy for head and neck cancer using in vivo 1H MR spectroscopy.Pretreatment and early intratreatment prediction of clinicopathologic response of head and neck cancer to chemoradiotherapy using 1H-MRS.Amide proton transfer-weighted imaging of the head and neck at 3 T: a feasibility study on healthy human subjects and patients with head and neck cancer.The use of dynamic tracer concentration in veins for quantitative DCE-MRI kinetic analysis in head and neck.Spontaneous necrosis of parathyroid adenoma: biochemical and imaging follow-up for two years.Measurement of synovial lining volume by magnetic resonance imaging of the knee in chronic synovitis.DCE-MRI for Pre-Treatment Prediction and Post-Treatment Assessment of Treatment Response in Sites of Squamous Cell Carcinoma in the Head and Neck.Imaging for primary hyperparathyroidism--what beginners should know.In vivo proton magnetic resonance spectroscopy of breast lesions: an update.Multimodality imaging of head and neck cancerImaging for staging and management of thyroid cancerNon-Gaussian analysis of diffusion weighted imaging in head and neck at 3T: a pilot study in patients with nasopharyngeal carcinoma.HER2 expression predicts improved survival in patients with cervical node-positive head and neck squamous cell carcinoma.Diffusion-weighted MR imaging in the head and neck.Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).State of the art MRI in head and neck cancer.Vascular lesions of parotid gland in adult patients: diagnosis with high-resolution ultrasound and MRI.Correlation of biomarkers in head and neck squamous cell carcinoma.Intracellular free magnesium of brain and cerebral phosphorus-containing metabolites after subarachnoid hemorrhage and hypermagnesemic treatment: a ³¹P–magnetic resonance spectroscopy study. Clinical article.Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer.Detection of Nasopharyngeal Carcinoma by MR Imaging: Diagnostic Accuracy of MRI Compared with Endoscopy and Endoscopic Biopsy Based on Long-Term Follow-Up.MRI of primary non-Hodgkin's lymphoma of the palatine tonsil.Cervical nodal volume for prognostication and risk stratification of patients with nasopharyngeal carcinoma, and implications on the TNM-staging system.Evolution of radiation-induced brain injury: MR imaging-based study.Hypoglossal nerve palsy in nasopharyngeal carcinoma.Concatenated and parallel optimization for the estimation of T1 map in FLASH MRI with multiple flip angles.Head and neck squamous cell carcinoma: diagnostic performance of diffusion-weighted MR imaging for the prediction of treatment response.A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy.Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma.Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma--correlation with excision repair cross-complementing-1 polymorphisms.In vivo 1H MR spectroscopy of thyroid carcinoma.Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group.The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis.Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha.Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer-a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria.
P50
Q26740275-BFCD345C-5DB3-413C-A084-4510FEADD702Q28075983-E186CFB7-62C9-443D-848F-C8B28CB34DF0Q30988006-394D0440-0853-4854-9951-120BEBC13EB5Q31012810-889CCE35-534D-4374-8680-D1F86A08A7BDQ31100093-E9626563-05AD-45CF-B85A-268617839D0DQ33490157-9FAF1847-97CA-4909-8986-7BD6E477F3F5Q33616442-8C6443D4-52BB-49D1-8E92-F394DDD762D9Q34160964-379F4E56-1B90-4B0B-A181-1B22525DD023Q34635573-7E93973E-AC8F-4057-9C34-1D0D78802EC7Q35507617-21BB5ED3-723E-4981-A3F8-044CF5FB9528Q35547434-CE6A08BF-D0F4-4180-8566-12E6501FEF90Q35866622-4E173659-2B5B-4316-89F5-B2ECD3B9DD5DQ35920363-F9489435-1879-4115-9098-1542C008AE3FQ36628257-CD663429-DF42-4B28-8DA3-F01168FDEA06Q36963774-55E11485-407A-45D1-9DDE-21AAA9559812Q37129052-75249E29-083B-4D9C-B479-19DC75179BD2Q37510711-62625477-BFB8-4AA4-B6F9-3CB0E90D666DQ37604597-67E6C2F6-3945-475C-B17B-B12AB32C5FAEQ37995998-4F22CACA-A601-45EC-92E0-6B8DCF9A8034Q38385856-ED923287-3A25-4AFF-9210-7EE5925678DCQ39401163-E2051D08-5406-4133-8639-8EDF730DC2CDQ39689191-E1897090-AAA0-40FD-9BE0-21C469EE0094Q39813250-1383DC2D-B268-4C74-8250-8B13DDF52687Q39929527-6511A758-8E3E-464E-9812-5394C9F5CA16Q40089200-129FA4AA-B4C5-4AD3-B748-B6535F0C652AQ40597632-FED40977-F5DD-4068-9335-F44B0F626AC6Q40603411-C9EE4AF1-8718-4EF5-8F82-99272F58604FQ41606792-B84CBCBE-723A-4BBA-AA67-BED298C7610DQ43697862-EB62743E-5D62-434A-B466-410ECB159C3CQ44371713-4AB553FB-ACD4-4FA7-A1E9-231DF981783DQ44917418-EC19AF3A-7D12-411F-9507-D95BF19332E1Q44941244-A2D47697-7D2C-4365-BB92-816AF9D4669CQ45400772-D26F8525-F77C-44DC-B844-3D995F4BBD70Q45411641-8033B800-E40A-4C29-B4CD-8A62529A1A81Q45956344-73CF8F1B-EEB2-4DFD-B475-34CE49D3A8E9Q46409897-6B910C54-BD62-4DA9-B152-9DB9358E5AD7Q46658593-A02DE8F4-18E4-4BD6-A72F-BFEC71820F52Q46698912-8D58AEE8-F06F-4D77-82D7-1AA9D75BA47AQ46869425-3B73B74A-311C-429C-A987-B4EA5930D6E4Q47925636-AC47C0B3-FAC8-490D-98AF-4A20B49DCA11
P50
description
researcher ORCID ID = 0000-0002-5280-8349
@en
name
Ann D King
@ast
Ann D King
@en
Ann D King
@nl
type
label
Ann D King
@ast
Ann D King
@en
Ann D King
@nl
prefLabel
Ann D King
@ast
Ann D King
@en
Ann D King
@nl
P31
P496
0000-0002-5280-8349